Immunohistochemical staining of Cytokeratin 20  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Cytokeratin 20 [KS 20.8] Antibody (cGMP).

$ 135.00$ 665.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD110
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG2a, kappa

Product NumberDescriptionPrice
QIVD110-0.1ml Size: 0.1 ml, Format: Concentrate $ 135.00
QIVD110-0.5ml Size: 0.5 ml, Format: Concentrate $ 405.00
QIVD110-1ml Size: 1 ml, Format: Concentrate $ 665.00
QIVD110-6ml Size: 6 ml, Format: Predilute $ 325.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD110-0.1ml
Cytokeratin 20 General Information
Alternate Names
Molecular Weight
48.5 kDa
Chromosomal Location
[chr: CHR_HSCHR17_4_CTG4] [chr_start: 40875941] [chr_end: 40885227] [strand: -1]; q21.2 [chr: 17] [chr_start: 40875941] [chr_end: 40885227] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolKRT20
Entrez Gene ID54474
RefSeq Protein Accession(s)NP_061883
RefSeq mRNA Accession(s)NM_019010;
RefSeq Genomic Accession(s)NW_003871091; NG_012286; NC_000017
UniProt ID(s)P35900
PharmGKB ID(s)PA134938907
KEGG Gene ID(s)hsa:54474
General Description of Cytokeratin 20 .
Cytokeratin 20 is less acidic than the other type I cytokeratins and is of particular interest because of its restricted range of expression. This antibody reacts with cytokeratin polypeptide of 46 kDa in immunoblot analyses. Studies have shown that a marked difference exists in the expression of Cytokeratin 20 among various carcinomas.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:25-1:50
Pretreatment HistoZyme
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Cytokeratin 20 Antibody Clone: KS 20.8
Host and Isotype: Mouse IgG2a, kappa
Recommended Positive Control Sample: Skin, Colon Carcinoma
Cellular Localization of Antibody KS 20.8 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: Cytokeratins isolated from human micro-dissected villi of human duodenal mucosa.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Cytokeratin 20 Information for Pathologists

Summary:

Epithelial marker (MW 46 kDa) with restricted expression compared to CK7 (OMIM #608218). Uses by pathologists General patterns (specificity varies). CK7+ / CK20+ in carcinomas of bile duct (extrahepatic / gallbladder, often, Pathol Res Pract 2003;199:65), lung-mucinous bronchioloalveolar (Am J Clin Pathol 2004;122:421), pancreas (Cancer 2006;106:693, but see Arch Pathol Lab Med 2000;124:1196). Urothelium (often, Arch Pathol Lab Med 2001;125:921, Hum Pathol 2002;33:1136).

Common Uses By Pathologists:

General patterns (specificity varies). CK7+ / CK20+ in carcinomas of bile duct (extrahepatic / gallbladder, often, Pathol Res Pract 2003;199:65), lung-mucinous bronchioloalveolar (Am J Clin Pathol 2004;122:421), pancreas (Cancer 2006;106:693, but see Arch Pathol Lab Med 2000;124:1196). Urothelium (often, Arch Pathol Lab Med 2001;125:921, Hum Pathol 2002;33:1136). Also primary mucinous tumors of ovary (74%), upper GI tract (78%) and endocervix (88%, Am J Surg Pathol 2006;30:1130). CK7+ / CK20- in carcinomas of bile duct (intrahepatic, Pathol Res Pract 2003;199:65), breast (Ann Diagn Pathol 1999;3:350), endocervical and endometrial adenocarcinoma (Pathol Res Pract 2003;199:65), esophagus (distal, Am J Surg Pathol 2002;26:1213), lung (not mucinous bronchioloalveolar, BMC Cancer 2006;6:31), salivary gland (Pathol Int 2005;55:386), thyroid (Appl Immunohistochem Mol Morphol 2000;8:189).

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Cytokeratin 20 [KS 20.8] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Phone: 1-855-344-1400 | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Cytokeratin 20 [KS 20.8] Antibody (cGMP).